Tronieri Jena Shaw, Alfaris Nasreen, Chao Ariana M, Pearl Rebecca L, Alamuddin Naji, Bakizada Zayna M, Berkowitz Robert I, Wadden Thomas A
Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, United States.
Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, United States.
Contemp Clin Trials. 2017 Aug;59:105-112. doi: 10.1016/j.cct.2017.06.004. Epub 2017 Jun 16.
BACKGROUND/AIMS: Few studies have examined the efficacy of recently approved medications for chronic weight management in facilitating the maintenance of lost weight. This paper provides an overview of the design and rationale for a trial investigating whether lorcaserin, when combined with behavioral weight loss maintenance sessions (WLM), will facilitate the maintenance of losses of ≥5% of initial weight.
In this two-phase trial, participants with obesity will enroll in a 14-week run-in diet program consisting of weekly group lifestyle modification sessions and a 1000-1200kcal/d meal replacement diet. Participants who complete this weight induction phase and lose at least 5% of initial weight will then be randomized to 52weeks of WLM plus lorcaserin or WLM plus placebo. We hypothesize that at 52weeks post randomization, participants assigned to WLM plus lorcaserin will achieve significantly better maintenance of the prior 5% weight loss.
We will recruit 182 adults with obesity to participate in the diet run-in, 136 of whom (75%) are expected to become eligible for the randomized controlled trial. Co-primary outcomes include the percentage of participants who maintain a loss of at least 5% of initial weight at week 52 and change in weight (kg) from randomization to week 52.
This two-phase design will allow us to determine the potential efficacy of chronic weight management using lorcaserin for maintaining initial losses of at least 5% body weight, induced by the use of a structured meal-replacement diet. This combined approach holds promise of achieving larger long-term weight losses.
NCT02388568 on ClinicalTrials.gov.
背景/目的:很少有研究探讨近期获批用于慢性体重管理的药物在促进体重减轻维持方面的疗效。本文概述了一项试验的设计和基本原理,该试验旨在研究氯卡色林与行为性体重减轻维持疗程(WLM)联合使用时,是否有助于维持初始体重至少5%的减轻。
在这项两阶段试验中,肥胖参与者将参加一个为期14周的预试验饮食计划,该计划包括每周一次的团体生活方式改变课程和每天1000 - 1200千卡的代餐饮食。完成这个体重诱导阶段并减轻至少5%初始体重的参与者随后将被随机分为接受52周的WLM加氯卡色林或WLM加安慰剂治疗。我们假设在随机分组后52周,分配到WLM加氯卡色林组的参与者在维持之前5%体重减轻方面会取得显著更好的效果。
我们将招募182名肥胖成年人参加饮食预试验,预计其中136人(75%)有资格参加随机对照试验。共同主要结局包括在第52周维持至少5%初始体重减轻的参与者百分比,以及从随机分组到第52周的体重变化(千克)。
这种两阶段设计将使我们能够确定使用氯卡色林进行慢性体重管理以维持由结构化代餐饮食诱导的至少5%体重初始减轻的潜在疗效。这种联合方法有望实现更大的长期体重减轻。
ClinicalTrials.gov上的NCT02388568。